Agile Therapeutics (AGRX) plunged after it said a Phase 3 study of its Twirla contraceptive patch scored a 4.8 using the Pearl Index, an index that shows the number of times the contraceptive fails over a calculated 100 years of use, worse than a competitors Pearl Index score of 3.19.